news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Economic Observer reporter Zhang Ling On August 27, two influenza vaccines produced by Sanofi's Pasteur were suspended. These two vaccines had been administered in Shanghai for about ten days.

The news was first announced to customers by Jiahui Medical, a high-end private medical institution, on the evening of August 26. A customer service staff member of Jiahui Medical told Economic Observer that at around 8 p.m. on the 26th, the hospital received an emergency notice from the Shanghai Municipal Center for Disease Control and Prevention, requiring the hospital to immediately suspend all Pasteur influenza vaccines (trivalent and quadrivalent), but the CDC did not disclose the specific reason for the suspension. Currently, all hospitals in Shanghai have suspended all Pasteur influenza vaccines.

On August 27, Sanofi responded to Economic Observer that during its ongoing stability study, it observed that the potency (reference data for the expected biological effect of the vaccine) of the trivalent influenza vaccine Valeline and the quadrivalent influenza vaccine Valeja for the 2024-2025 influenza season showed a downward trend. It is expected that the efficacy of the vaccine may be affected before the end of the product's validity period. As a preventive measure, it decided to temporarily suspend the supply and sale of these vaccines in China.

A large proportion of the people who received the two flu vaccines that were suspended were children. Valeline is suitable for adults and children over 36 months old, and Valejia is suitable for people aged 6 months and above.